---
title: "Altamira Therapeutics moves from Nasdaq to OTCQB"
url: "https://aibio.space/news/altamira-therapeutics-moves-nasdaq-otcqb-after-panel-decision/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2024-12-20"
section: "Listings"
tickers: "OTC:CYTOF"
source: "https://www.sec.gov/Archives/edgar/data/1601936/000121390024110771/ea022551401ex99-1_altamira.htm"
summary: "The Nasdaq Hearings Panel denied the company's request to stay listed over the $1.00 minimum bid price rule. Shares are to trade as CYTOF, and the company"
---

By the aibio.space news desk.

Sources

- [Altamira Therapeutics Ltd. 6-K (2024-12-20)](https://www.sec.gov/Archives/edgar/data/1601936/000121390024110771/ea022551401ex99-1_altamira.htm)

[CYTOF](https://aibio.space/companies/altamira-therapeutics/)

2024-12-20

# Altamira Therapeutics moves from Nasdaq to OTCQB after panel decision

Tickers [CYTOF](https://aibio.space/companies/altamira-therapeutics/)

The Nasdaq Hearings Panel denied the company's request to stay listed over the $1.00 minimum bid price rule. Shares are to trade as CYTOF, and the company says it plans no reverse stock split.

## Key facts

- **Company**: Altamira Therapeutics Ltd. (OTC: CYTOF)

- **News type**: Listings

- **Primary source**: [Altamira Therapeutics Ltd. 6-K (2024-12-20)](https://www.sec.gov/Archives/edgar/data/1601936/000121390024110771/ea022551401ex99-1_altamira.htm)

*The White House and its lawn. CC0, via rawpixel. The picture shows the field, not the companies named.*

Altamira Therapeutics Ltd. said on December 20, 2024 that its common shares will be delisted from Nasdaq at the open of trading that day and are expected to begin trading on the OTCQB marketplace under the symbol CYTOF. The company said shareholders need not take any action.

On December 18, 2024, the company received notice that the Nasdaq Hearings Panel had decided to delist the shares for failure to comply with Rule 5550(a)(2), which requires listed securities to keep a minimum bid price of $1.00 per share. Nasdaq had sent a delisting notification on September 30, 2024, and the company appealed to the Panel to present a plan for regaining compliance. The Panel denied its request to stay listed.

OTCQB is one of three marketplaces for over-the-counter stocks run by OTC Markets Group.

Founder, Chief Executive Officer and Chairman Thomas Meyer said the $1 minimum bid price rule does not apply to OTCQB companies, so "there is no requirement to perform any reverse stock split."

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

CYTOF

Altamira Therapeutics Ltd.

OTC · Bermuda

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/altamira-therapeutics-moves-nasdaq-otcqb-after-panel-decision/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Altamira Therapeutics moves from Nasdaq to OTCQB", 2024-12-20, https://aibio.space/news/altamira-therapeutics-moves-nasdaq-otcqb-after-panel-decision/